Not Great News For Vanda

Vanda Pharmaceuticals (VNDA) shares moved lower today after a negative report from market research firm Aurelius Value. Aurelius disclosed that it holds a short position in the stock, and alleges that VNDA’s CEO has engaged in fraudulent schemes along with his company as a whole. Here’s a recap.